立体定向放射外科联合PD-(L)1抑制剂治疗脑转移:黑色素瘤与其他肿瘤的疗效与毒性比较
该回顾性研究纳入41例黑色素瘤脑转移患者(153个病灶)和33例非小细胞肺癌或肾细胞癌脑转移患者(118个病灶),2014至2019年接受立体定向放射外科联合抗PD-1/PD-L1治疗(两种治疗间隔小于4个月)。结果显示1年局部控制率90.3%,1年远处控制率38.8%,1年无高级别毒性率患者为90.4%、病灶为94.6%;
要点
- 立体定向放射外科联合抗PD-1/PD-L1抑制剂1年局部控制率90.3%,高级别中枢神经系统毒性低。
核心结论
- 立体定向放射外科联合抗PD-1免疫检查点抑制剂可获得较高的局部肿瘤控制率和较低的高级别中枢神经系统毒性率,与既往单纯放射外科系列相当。
- 黑色素瘤患者发生高级别毒性的可能性高于肾细胞癌和非小细胞肺癌患者。
研究设计与样本
- 回顾性研究,纳入2014至2019年41例黑色素瘤脑转移患者(153个未接受过放疗的病灶)和33例非小细胞肺癌或肾细胞癌脑转移患者(118个病灶)。
- 患者接受立体定向放射外科联合抗PD-1受体抑制或抗PD-L1抑制,两种治疗间隔小于4个月。
主要发现
- 中位随访10个月(范围1-41个月),1年局部控制率估计为90.3%,1年远处控制率为38.8%。
- 1年无高级别毒性率患者为90.4%,病灶为94.6%。
- 发生高级别毒性的患者具有高肿瘤负荷、激进类固醇减量及接受伊匹木单抗治疗的某些组合特征。
关键数值与推荐
- 高级别中枢神经系统毒性定义为不可逆的3级或任何4/5级神经系统事件,类似RTOG 9005标准。
- 挽救性切除显示坏死和存活肿瘤被视为4级毒性和局部失败。
- 对比增强磁共振成像上最大横断面直径增加25%定义为局部失败。
临床怎么用
- 立体定向放射外科联合抗PD-1/PD-L1抑制剂可用于黑色素瘤、非小细胞肺癌和肾细胞癌脑转移,局部控制率高且高级别毒性低。
- 对黑色素瘤脑转移患者联合治疗时应更密切监测高级别中枢神经系统毒性,尤其在高肿瘤负荷、激进类固醇减量或联合伊匹木单抗时。
局限性
- 中位随访仅10个月,随访时间较短。
- 高级别毒性相关因素的分析基于少数事件,需前瞻性研究进一步验证治疗时机、类固醇和反应等问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prior studies have mixed conclusions about the efficacy and central nervous system (CNS) toxicity profile of combining radiosurgery with anti-programed cell death 1 (PD-1) immune checkpoint inhibition (ICI) for brain metastases. This study evaluates the safety and efficacy of combined radiosurgery and anti-PD-1 ICI for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) brain metastases (BM). METHODS AND MATERIALS: Forty-one patients with 153 radiation naïve melanoma BM and 33 patients with 118 BM of NSCLC and RCC origin from 2014 through 2019 received radiosurgery and either anti PD-1 receptor inhibition or anti PD-L1 inhibition targeting the PD-1 ligand with less than 4 months separating either therapy. Similar to Radiation Therapy Oncology Group 9005, high-grade CNS toxicity was defined as irreversible grade 3 or any grade 4/5 neurologic event. Salvage resection revealing necrosis and viable tumor was considered grade 4 toxicity and local failure. An increase in greatest cross-sectional diameter of 25% on contrasted magnetic resonance imaging was designated as a local failure. RESULTS: Median follow-up was 10 months (range, 1-41 months). Local control was estimated to be 90.3% at 1 year. Distant control was 38.8% at 1 year, and neither local nor distant control were significantly influenced by limiting steroids to the day of treatment (P = .55, .52 respectively). One-year freedom from high-grade toxicity was 90.4% for patients and 94.6% for tumors. Though melanoma accounted for 41 (55%) patients and 153 (56%) tumors, it accounted for all high-grade toxicities (P = .03). These patients had some combination of high tumor burden, aggressive steroid taper, and treatment with ipilimumab. CONCLUSIONS: Stereotactic radiosurgery combined with anti-PD-1 ICI appears to result in a high rate of local tumor control and a low rate of high-grade CNS toxicity, comparable to historical series with radiosurgery alone. High-grade toxicity is more likely in melanoma than RCC and NSCLC. Coming prospective studies will shed light on further questions about treatment timing, steroids, and response.
引用
- Travis RL, Marcrom SR, Brown MH, et al. Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition. Adv Radiat Oncol. 2020. PMID: 33665483. doi:10.1016/j.adro.2020.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。